

Anti-BCRABL [7c6] rAb

Catalogue number: 153261

Sub-type: Primary antibody

Images:

Contributor

Inventor: Susheela Dhut

Institute: Absolute Antibody ; Queen Mary University of London

Images:

Tool details

***FOR RESEARCH USE ONLY**

Name: Anti-BCRABL [7c6] rAb

Alternate name:

Class: Recombinant

Conjugate: Unconjugated

Description: Recombinant antibody directed against BCR-ABL oncoprotein. Background and Research Application The BCR gene is involved in the 9:22 translocation that generates the Philadelphia chromosome both in chronic myeloid leukaemia (CML) and in a proportion of cases of acute lymphocytic leukaemia (ALL). A 5' bcr sequence becomes fused to an abl sequence (including tyrosine kinase domain sequences) from chromosome 9. This results in the production of a chimeric BCR-ABL oncoprotein with constitutively active tyrosine kinase activity. This is a recombinant version of anti-BCRABL monoclonal antibody. Anti-BCRABL antibody may be useful for studies of the oncogene and have potential diagnostic and prognostic applications, particularly within leukaemia. This antibody is specific for the SSINEEITPRRQS epitope of BCR (residues 686-696), and as such is able to recognise full-length BCR and the p210 form of the BCR-ABL fusion protein.

Purpose:

Parental cell:

Organism:

Tissue:

Model:

Gender:

Isotype: IgG2a

Reactivity: Human

Selectivity:

Host: Mouse

Immunogen: Bcr686 thyroglobulin conjugate

Immunogen UNIPROT ID:

Q62199

Sequence:

Growth properties:

Production details:

Formulation:

Recommended controls:

Bacterial resistance:

Selectable markers:

Additional notes:

Target details

Target: BCRABL

Target alternate names:

Target background: Recombinant antibody directed against BCR-ABL oncoprotein. Background and Research Application The BCR gene is involved in the 9:22 translocation that generates the Philadelphia chromosome both in chronic myeloid leukaemia (CML) and in a proportion of cases of acute lymphocytic leukaemia (ALL). A 5' bcr sequence becomes fused to an abl sequence (including tyrosine kinase domain sequences) from chromosome 9. This results in the production of a chimeric BCR-ABL oncoprotein with constitutively active tyrosine kinase activity. This is a recombinant version of anti-BCRABL monoclonal antibody. Anti-BCRABL antibody may be useful for studies of the oncogene and have potential diagnostic and prognostic applications, particularly within leukaemia. This antibody is specific for the SSINEITPRRQS epitope of BCR (residues 686-696), and as such is able to recognise full-length BCR and the p210 form of the BCR-ABL fusion protein.

Molecular weight:

Ic50:

Applications

Application: IF ; IP ; WB

Application notes:

Handling

Format: Liquid

Concentration: 1 mg/ml

Passage number:

Growth medium:

Temperature:

Atmosphere:

Volume:

Storage medium:

Storage buffer: PBS

Storage conditions: Store at -20° C frozen. Avoid repeated freeze / thaw cycles

Shipping conditions: Shipping at 4° C

Related tools

Related tools: Anti-BCRABL [7c6]

References

References: Original hybridoma first published in: Hogg et al. 1989. Eur J Immunol. 19(6):1053-61. PMID: 2666142.

CancerTools.org